Primary ciliary dyskinesia-retinitis pigmentosa syndrome

Primary ciliary dyskinesia-retinitis pigmentosa syndrome (also known as PCD-RP syndrome or ciliary dyskinesia with retinitis pigmentosa) is an extremely rare genetic disorder that combines features of two distinct ciliopathies: primary ciliary dyskinesia (PCD) and retinitis pigmentosa (RP). This condition affects both the motile cilia found throughout the respiratory tract and the sensory cilia (photoreceptors) in the retina. Because motile cilia are dysfunctional, affected individuals experience chronic respiratory problems including recurrent sinusitis, bronchiectasis, chronic otitis media, and impaired mucociliary clearance. Some patients may also present with situs inversus (mirror-image reversal of internal organs), reflecting the role of cilia in establishing left-right body asymmetry during embryonic development. The retinitis pigmentosa component leads to progressive degeneration of the rod and cone photoreceptors in the retina, causing night blindness, progressive peripheral visual field loss, and eventual central vision impairment. This syndrome belongs to the broader group of ciliopathies — disorders caused by defects in the structure or function of cilia. The co-occurrence of PCD and RP highlights the shared ciliary biology underlying both conditions, as both motile and sensory cilia depend on overlapping molecular pathways for their assembly and function. Mutations in genes involved in ciliary structure or intraflagellar transport may simultaneously disrupt respiratory cilia motility and photoreceptor function. There is currently no cure for this syndrome. Management is supportive and multidisciplinary, involving pulmonologists and ophthalmologists. Respiratory care includes airway clearance techniques, prompt treatment of respiratory infections with antibiotics, and monitoring for bronchiectasis. Ophthalmologic management focuses on monitoring retinal degeneration, low-vision aids, and genetic counseling. Research into gene therapy for both PCD and RP components is ongoing but no approved targeted therapies are currently available for this combined syndrome.

Common questions about Primary ciliary dyskinesia-retinitis pigmentosa syndrome